Scrutinizing the SARS-CoV-2 protein information for the designing an effective vaccine encompassing both the T-cell and B-cell epitopes

Neha Jain; Uma Shankar; Prativa Majee; Amit Kumar

. CC-BY-ND 4.0 International license author/funder. It is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.26.009209 doi: bioRxiv preprint SARS-CoV-2 that causes COVID-19 has recently emerged as one of the deadliest pathogens severely affecting humans worldwide. The SARS-CoV-2 is highly contagious virus with a high mortality rate especially in immunocompromised and elderly persons. Vaccines are the utmost need of the time to succumb the rising infections due to COVID-19 and represent the best way to combat infectious diseases in the community. Conventional vaccine development methods are time-consuming, laborious and expensive and in this regard, the in-silico immuno-informatics approach have proved to a boon [59] . Moreover, the availability of large number of efficient tools to predict the immuno-determinants, and large database of information facilitate and accelerate this whole process of vaccine designing [60] . Multiepitope vaccines are designed by using the most antigenic conserved part of the pathogen's proteins that makes them more effective and can help in combating the high mutation rate in RNA viruses. These epitope-based vaccines have added advantages of being safe, stable, highly specific, cost-curtailing, easy to produce in bulk, and provides option to manipulate the epitopes for designing of a better vaccine candidate [61] . This method of vaccine development has proved to be promising enough for different microbial diseases including both bacterial and viral [25, [62] [63] [64] [65] [66] [67] .